Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 20, 2022 - Issue 11
Submit an article Journal homepage
1,759
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Real-world implementation of dolutegravir plus lamivudine in people living with HIV in Southwest China

Xiaoyan Yanga School of Public Health, the Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, Guizhou Medical University, Guiyang, Guizhou, ChinaORCID Iconhttps://orcid.org/0000-0003-3483-5658View further author information
ORCID Icon,
Yanhua Fub Department of Infection, Guiyang Public Health Clinical Center, Guiyang, Guizhou, ChinaView further author information
,
Xiaoxin Xieb Department of Infection, Guiyang Public Health Clinical Center, Guiyang, Guizhou, ChinaView further author information
,
Lin Ganb Department of Infection, Guiyang Public Health Clinical Center, Guiyang, Guizhou, ChinaView further author information
,
Chunli Songb Department of Infection, Guiyang Public Health Clinical Center, Guiyang, Guizhou, ChinaView further author information
,
Yebing Songb Department of Infection, Guiyang Public Health Clinical Center, Guiyang, Guizhou, ChinaView further author information
,
Jun Lia School of Public Health, the Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, Guizhou Medical University, Guiyang, Guizhou, ChinaView further author information
&
Hai Longb Department of Infection, Guiyang Public Health Clinical Center, Guiyang, Guizhou, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5744-5623View further author information
ORCID Icon show all
Pages 1501-1508 | Received 06 Jul 2022, Accepted 16 Sep 2022, Published online: 29 Sep 2022

References

  • Acquired Immunodeficiency Syndrome and Hepatitis C. Professional group, society of infectious diseases, Chinese medical association Chinese center for disease control and prevention. Chinese guidelines for diagnosis and treatment of human immunodeficiency virus infection/acquired immunodeficiency syndrome (2021 edition). Chinese J AIDS & STD. 2021;27(11): 1182–1201.
  • Trickey A, May MT, Vehreschild -J-J, et al. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies [J]. Lancet HIV. 2017;4(8):e349–e356.
  • Hidalgo-Tenorio C, Cortés LL, Gutiérrez A, et al. DOLAMA study: effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients [J]. Medicine (Baltimore). 2019;98(32):32.
  • Joly V, Burdet C, Landman R, et al. Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL) [J]. J Antimicrob Chemother. 2019;74(3):739–745.
  • Nyaku AN, Zheng L, Gulick RM, et al. Dolutegravir plus lamivudine for initial treatment of HIV-1 infected participants with HIV-1 RNA< 500 000 copies/mL: week 48 outcomes from ACTG 5353 [J]. J Antimicrob Chemother. 2019;74(5):1376–1380.
  • Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials [J]. Lancet. 2019;393(10167):143–155 .
  • Van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide–based 3-or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO Study [J]. Clin Infect Dis. 2020;71(8):1920–1929.
  • Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV [EB/OL]. [2019 November 20]. http://aidsinfo.nih.gov/contentfiles/lvguildelines/Adultand/Adolescent-GL.pdf
  • Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel [J]. JAMA. 2018;320(4):379–396.
  • Punekar YS, Parks D, Joshi M, et al. Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence [J]. HIV Med. 2021;22(6):423–433.
  • Patel R, Evitt L, Mariolis I, et al. HIV treatment with the two-drug regimen dolutegravir plus lamivudine in real-world clinical practice: a systematic literature review [J]. Infect Dis Ther. 2021;10(4):2051–2070.
  • Junren ZHU, Runlin GAO, Shuiping ZHAO, et al. Chinese guidelines for the prevention and treatment of dyslipidemia in adults (2016 revision) [J]. Circ J. 2016;31(10):937–953.
  • Jeon YK, Kim BH, Kim IJ. The diagnosis of osteoporosis[J]. J Korean Med Sci. 2016;59:11.
  • Rolle CP, Berhe M, Singh T, et al. Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV[J]. AIDS. 2021;35(12):1957.
  • Jenks JD, Hoenigl M. CD4: CD8 ratio and CD8+ cell count for prognosticating mortality in HIV- infected patients on antiretroviral therapy [J]. J Lab Precis Med. 2018;3: 8.
  • Cahn P, Rolón MJ, Figueroa MI, et al. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study [J]. J Int AIDS Soc. 2017;20(1):21678.
  • Bin WANG. Analysis of efficacy and influencing factors of HAART in AIDS patients [J]. Chinese J AIDS & STD. 2017;23(8):760–761.
  • Joya C, Won SH, Schofield C, et al. Persistent low-level viremia while on antiretroviral therapy is an independent risk factor for virologic failure [J]. Clin Infect Dis. 2019;69(12):2145–2152.
  • Maggiolo F, Gulminetti R, Pagnucco L, et al. Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients [J]. BMC Infect Dis. 2017;17(1):215.
  • Zamora FJ, Dowers E, Yasin F, et al. Dolutegravir and lamivudine combination for the treatment of HIV-1 infection [J]. HIV AIDS (Auckl). 2019;11:255.
  • Zhang M, Deng Q, Wang L, et al. Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: a nationally representative survey of 163, 641 adults [J]. Int J Cardiol. 2018 Jun 1;260:196–203.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.